Neurodegenerative disease management, pages 1-10

Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice

Moein Amin ^{1, 2}

HARVEY TUCKER ^{2, 3}

Dan Michael Pineda ^{4, 5}

Ming-Hui Tai ^{6, 7}

Qiujun Shao ^{6, 7}

Brandon Brown ^{6, 7}

Abhijit Gadkari ^{6, 7}

Brandon Moss ^{1, 2}

Devon S Conway ^{1, 2}

Carrie M Hersh ^{2, 8}

Show full list: 10 authors

Hide authors affiliations

Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA |

CLEVELAND CLINIC |

Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA |

⁴

Department of Neurology, Lahey Hospital and Medical Center, Burlington, MA, USA |

⁵

Lahey Hospital and Medical Center

⁶

Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA |

⁷

Novartis Pharmaceuticals Corporation

⁸

Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA, USA |

Publication type: Journal Article

Publication date: 2025-01-21

Taylor & Francis

Journal: Neurodegenerative disease management

scimago Q2

SJR: 0.618

CiteScore: 4.3

Impact factor: 2.3

ISSN: 17582024, 17582032

DOI: 10.1080/17582024.2025.2452150

Copy DOI

Found

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST | RIS | BibTex

Found error?

Publisher

Taylor & Francis

Journal

Neurodegenerative disease management

scimago Q2

SJR

0.618

CiteScore

4.3

Impact factor

2.3

ISSN

17582024 (Print)

17582032 (Electronic)